In 2010, we have the clinical opportunity to choose among several “targeted” agents when treating patients with metastatic renal cell carcinoma (RCC).
ASCO Annual Meeting: Genitourinary
Newly developed targeted agents in the management of advanced renal cell carcinoma have given us treatment options in this disease not imagined a decade ago.
Advertisement
Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data
2
Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?
3
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
4
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
5
